Cargando…
Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn
Background: Recognizing a change in serum creatinine concentrations is useful to detect a renal adverse drug reaction signal. Assessing and characterizing the nephrotoxic side-effects of drugs in extremely low birth weight (ELBW, ≤1000 g) neonates remain challenging due to the high variability in cr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868337/ https://www.ncbi.nlm.nih.gov/pubmed/33569003 http://dx.doi.org/10.3389/fphar.2020.610294 |
_version_ | 1783648432670375936 |
---|---|
author | van Donge, Tamara Allegaert, Karel Pfister, Marc Smits, Anne van den Anker, John |
author_facet | van Donge, Tamara Allegaert, Karel Pfister, Marc Smits, Anne van den Anker, John |
author_sort | van Donge, Tamara |
collection | PubMed |
description | Background: Recognizing a change in serum creatinine concentrations is useful to detect a renal adverse drug reaction signal. Assessing and characterizing the nephrotoxic side-effects of drugs in extremely low birth weight (ELBW, ≤1000 g) neonates remain challenging due to the high variability in creatinine in this population. This study aims to investigate and quantify the impact of ibuprofen treatment on kidney function, reflected by serum creatinine. Method: A recently developed dynamical model for serum creatinine was used to simulate creatinine profiles for typical, reference ELBW neonates with varying gestational and postnatal ages whilst being exposed to ibuprofen treatment. Results: The increase of serum creatinine concentrations due to ibuprofen treatment is most apparent during the first week of life. The difference in serum creatinine values between ibuprofen-exposed vs. non-exposed neonates decreases with increasing postnatal age, independent of gestational age. Conclusion: The difference in serum creatinine concentrations between ibuprofen-exposed vs. non-exposed neonates decreases with postnatal age, indicating an increased clearing capacity and resulting in a weak ibuprofen-related adverse drug reaction signal beyond early neonatal life. |
format | Online Article Text |
id | pubmed-7868337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78683372021-02-09 Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn van Donge, Tamara Allegaert, Karel Pfister, Marc Smits, Anne van den Anker, John Front Pharmacol Pharmacology Background: Recognizing a change in serum creatinine concentrations is useful to detect a renal adverse drug reaction signal. Assessing and characterizing the nephrotoxic side-effects of drugs in extremely low birth weight (ELBW, ≤1000 g) neonates remain challenging due to the high variability in creatinine in this population. This study aims to investigate and quantify the impact of ibuprofen treatment on kidney function, reflected by serum creatinine. Method: A recently developed dynamical model for serum creatinine was used to simulate creatinine profiles for typical, reference ELBW neonates with varying gestational and postnatal ages whilst being exposed to ibuprofen treatment. Results: The increase of serum creatinine concentrations due to ibuprofen treatment is most apparent during the first week of life. The difference in serum creatinine values between ibuprofen-exposed vs. non-exposed neonates decreases with increasing postnatal age, independent of gestational age. Conclusion: The difference in serum creatinine concentrations between ibuprofen-exposed vs. non-exposed neonates decreases with postnatal age, indicating an increased clearing capacity and resulting in a weak ibuprofen-related adverse drug reaction signal beyond early neonatal life. Frontiers Media S.A. 2021-01-25 /pmc/articles/PMC7868337/ /pubmed/33569003 http://dx.doi.org/10.3389/fphar.2020.610294 Text en Copyright © 2021 van Donge, Allegaert, Pfister, Smits and van den Anker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology van Donge, Tamara Allegaert, Karel Pfister, Marc Smits, Anne van den Anker, John Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title | Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title_full | Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title_fullStr | Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title_full_unstemmed | Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title_short | Creatinine Trends to Detect Ibuprofen-Related Maturational Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn |
title_sort | creatinine trends to detect ibuprofen-related maturational adverse drug events in neonatal life: a simulation study for the elbw newborn |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868337/ https://www.ncbi.nlm.nih.gov/pubmed/33569003 http://dx.doi.org/10.3389/fphar.2020.610294 |
work_keys_str_mv | AT vandongetamara creatininetrendstodetectibuprofenrelatedmaturationaladversedrugeventsinneonatallifeasimulationstudyfortheelbwnewborn AT allegaertkarel creatininetrendstodetectibuprofenrelatedmaturationaladversedrugeventsinneonatallifeasimulationstudyfortheelbwnewborn AT pfistermarc creatininetrendstodetectibuprofenrelatedmaturationaladversedrugeventsinneonatallifeasimulationstudyfortheelbwnewborn AT smitsanne creatininetrendstodetectibuprofenrelatedmaturationaladversedrugeventsinneonatallifeasimulationstudyfortheelbwnewborn AT vandenankerjohn creatininetrendstodetectibuprofenrelatedmaturationaladversedrugeventsinneonatallifeasimulationstudyfortheelbwnewborn |